The sole responsibility for the software, including any CDT-4 and other content contained therein, is with (insert name of applicable entity) or the CMS
Metabolism: Clinical and Experimental, 57 (5), 712-717
TB-4: Clinical Data for Unrelated Endpoints Meaningful human trial data for full-length TB-4 (corneal-healing Phase 2/3 as RGN-259, plus cardiac and wound-repair programs) Clean Phase 1 safety Cosmetic dosing is extrapolated from these programs Note: Full-length trial data does not transfer to the TB-500 fragment, so verify vial identity
Clinically studied in humans with proven safety records Legally available and WADA-compliant Support recovery and joint health without the unknown hormonal or reproductive risks Can be stacked synergistically for muscle preservation, connective tissue support, and long-term wellness Conclusion: Should Women Consider BPC-157 or TB-500
Kumar GG, et al
The human tripeptide GHK-Cu in prevention of oxidative stress and cancer